Cargando…

PARIS score for evaluation of probability of SARS-CoV-2 infection in cancer patients

Control of transmissible diseases as COVID-19 needs a testing and an isolation strategy. The PARIS score developed by Torjdman et al. was aimed at improving patient selection for testing and quarantining but was derived from a general population. We performed a retrospective analysis of the validity...

Descripción completa

Detalles Bibliográficos
Autores principales: Gueuning, Candice, Ameye, Lieveke, Loizidou, Angela, Grigoriu, Bogdan, Meert, Anne-Pascale
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9178543/
https://www.ncbi.nlm.nih.gov/pubmed/35678883
http://dx.doi.org/10.1007/s00520-022-07199-9
_version_ 1784723081314435072
author Gueuning, Candice
Ameye, Lieveke
Loizidou, Angela
Grigoriu, Bogdan
Meert, Anne-Pascale
author_facet Gueuning, Candice
Ameye, Lieveke
Loizidou, Angela
Grigoriu, Bogdan
Meert, Anne-Pascale
author_sort Gueuning, Candice
collection PubMed
description Control of transmissible diseases as COVID-19 needs a testing and an isolation strategy. The PARIS score developed by Torjdman et al. was aimed at improving patient selection for testing and quarantining but was derived from a general population. We performed a retrospective analysis of the validity of the PARIS score in a cancer patient population. We included 164 patients counting for 181 visits at the emergency department of the Jules Bordet Institute between March 10th and May 18th which had a SARS-CoV-2 RT-PCR test at admission. Twenty-six cases (14.3%) were tested positive with a higher proportion of positive tests among hematological patients compared to those with solid tumors (26% vs 11% p = 0.02). No clinical symptoms were associated with a positive SARS-CoV-2 PCR. No association between anticancer treatment and SARS-CoV-2 infection was found. The PARIS score failed to differentiate SARS-CoV-2-positive and SARS-CoV-2-negative groups (AUC 0.61 95% CI 0.48–0.73). The negative predictive value of a low probability PARIS score was 0.89 but this concerned only 11% of the patients. A high probability PARIS score concerned 49% patients but the positive predictive value was 0.18. CT scan had a sensitivity of 0.77, specificity 0.51, a positive predictive value of 0.24, and a negative predictive value of 0.92. The performance of the PARIS score is thus very poor in this cancer population. A low-risk score can be of some utility but this concerns a minority of patients.
format Online
Article
Text
id pubmed-9178543
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-91785432022-06-09 PARIS score for evaluation of probability of SARS-CoV-2 infection in cancer patients Gueuning, Candice Ameye, Lieveke Loizidou, Angela Grigoriu, Bogdan Meert, Anne-Pascale Support Care Cancer Original Article Control of transmissible diseases as COVID-19 needs a testing and an isolation strategy. The PARIS score developed by Torjdman et al. was aimed at improving patient selection for testing and quarantining but was derived from a general population. We performed a retrospective analysis of the validity of the PARIS score in a cancer patient population. We included 164 patients counting for 181 visits at the emergency department of the Jules Bordet Institute between March 10th and May 18th which had a SARS-CoV-2 RT-PCR test at admission. Twenty-six cases (14.3%) were tested positive with a higher proportion of positive tests among hematological patients compared to those with solid tumors (26% vs 11% p = 0.02). No clinical symptoms were associated with a positive SARS-CoV-2 PCR. No association between anticancer treatment and SARS-CoV-2 infection was found. The PARIS score failed to differentiate SARS-CoV-2-positive and SARS-CoV-2-negative groups (AUC 0.61 95% CI 0.48–0.73). The negative predictive value of a low probability PARIS score was 0.89 but this concerned only 11% of the patients. A high probability PARIS score concerned 49% patients but the positive predictive value was 0.18. CT scan had a sensitivity of 0.77, specificity 0.51, a positive predictive value of 0.24, and a negative predictive value of 0.92. The performance of the PARIS score is thus very poor in this cancer population. A low-risk score can be of some utility but this concerns a minority of patients. Springer Berlin Heidelberg 2022-06-09 2022 /pmc/articles/PMC9178543/ /pubmed/35678883 http://dx.doi.org/10.1007/s00520-022-07199-9 Text en © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Original Article
Gueuning, Candice
Ameye, Lieveke
Loizidou, Angela
Grigoriu, Bogdan
Meert, Anne-Pascale
PARIS score for evaluation of probability of SARS-CoV-2 infection in cancer patients
title PARIS score for evaluation of probability of SARS-CoV-2 infection in cancer patients
title_full PARIS score for evaluation of probability of SARS-CoV-2 infection in cancer patients
title_fullStr PARIS score for evaluation of probability of SARS-CoV-2 infection in cancer patients
title_full_unstemmed PARIS score for evaluation of probability of SARS-CoV-2 infection in cancer patients
title_short PARIS score for evaluation of probability of SARS-CoV-2 infection in cancer patients
title_sort paris score for evaluation of probability of sars-cov-2 infection in cancer patients
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9178543/
https://www.ncbi.nlm.nih.gov/pubmed/35678883
http://dx.doi.org/10.1007/s00520-022-07199-9
work_keys_str_mv AT gueuningcandice parisscoreforevaluationofprobabilityofsarscov2infectionincancerpatients
AT ameyelieveke parisscoreforevaluationofprobabilityofsarscov2infectionincancerpatients
AT loizidouangela parisscoreforevaluationofprobabilityofsarscov2infectionincancerpatients
AT grigoriubogdan parisscoreforevaluationofprobabilityofsarscov2infectionincancerpatients
AT meertannepascale parisscoreforevaluationofprobabilityofsarscov2infectionincancerpatients